4.5 Review

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens

Journal

EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 2, Pages 225-243

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.2.225

Keywords

drug-resistant Streptococcus pneumoniae; glycopeptide-resistant cocci; MRSA; multi-drug resistant pathogens; new antibiotics; oritavancin; VISA/GISA; VRE

Ask authors/readers for more resources

Nosocomial and community-acquired infections caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus spp. and Enterococcus spp. Oritavancin, a new parenteral semisynthetic glycopeptide, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci - vancomycin-resistant enterococci included - and Clostridia spp.) irrespective of their resistance status to the precursor molecule of vancomycin, is expected to file a new drug application by the first trimester of 2008. Once-daily dosing, good penetration into macrophages, in vitro activity against bacteria embedded in biofilms and low adverse reaction potential are further considered as oritavancin's advantages over existing drugs. While waiting for the results of supplementary Phase III studies to be announced, preliminary reports suggest the new drug will be a welcome addition to the existing antimicrobial armamentarium against Gram-positive cocci.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Microbiology

Population Pharmacokinetics of Fosfomycin in Critically Ill Patients

Suzanne L. Parker, Frantzeska Frantzeskaki, Steven C. Wallis, Chryssa Diakaki, Helen Giamarellou, Despoina Koulenti, Ilias Karaiskos, Jeffrey Lipman, George Dimopoulos, Jason A. Roberts

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

Article Microbiology

Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients

Ilias Karaiskos, Lena E. Friberg, Konstantinos Pontikis, Konstantinos Ioannidis, Vasiliki Tsagkari, Lamprini Galani, Eirini Kostakou, Fotini Baziaka, Charalambos Paskalis, Antonia Koutsoukou, Helen Giamarellou

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

Article Critical Care Medicine

The Association Between Colonization With Carbapenemase-Producing Enterobacteriaceae and Overall ICU Mortality: An Observational Cohort Study

Mirjam J. D. Dautzenberg, Ann N. Wekesa, Marek Gniadkowski, Anastasia Antoniadou, Helen Giamarellou, George L. Petrikkos, Anna Skiada, Christian Brun-Buisson, Marc J. M. Bonten, Lennie P. G. Derde

CRITICAL CARE MEDICINE (2015)

Article Pharmacology & Pharmacy

Plazomicin: an investigational therapy for the treatment of urinary tract infections

Ilias Karaiskos, Maria Souli, Helen Giamarellou

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)

Letter Infectious Diseases

High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections

Christina Routsi, Stelios Kokkoris, Evangelia Douka, Foteini Ekonomidou, Ilias Karaiskos, Helen Giamarellou

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)

Article Infectious Diseases

Molecular epidemiology of MRSA in 13 ICUs from eight European countries

D. J. Hetem, L. P. G. Derde, J. Empel, A. Mroczkowska, M. Orczykowska-Kotyna, A. Kozinska, W. Hryniewicz, H. Goossens, M. J. M. Bonten

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)

Article Infectious Diseases

Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012-2013

Maria Souli, Ilias Karaiskos, Lambrini Galani, Sofia Maraki, Efstathia Perivolioti, Athina Argyropoulou, Athina Charissiadou, Levantia Zachariadou, Sofia Tsiplakou, Vassiliki Papaioannou, Helen Tsorlini, Helen Katsifa, Vasiliki Baka, Paraskevi Pantazi, Angeliki Paschali, Anna Kyratsa, Eleftheria Trikka-Graphakos, Panagiota Giannopoulou, Evangelos Vogiatzakis, Helen Moraitou, Helen Papadogeorgaki, Helen Avgerinou, Theofano Panagea, Angeliki Pantazatou, Efthymia Petinaki, Giannoula Stamatopoulou, Marina Toutouza, Ioanna Karatzoglou, Konstantina Kontopoulou, Maria Orfanidou, Irene Karantani, Panteleimon Fytas, Konstantina Tzanetou, Evangelia Platsouka, Polyzo Kazila, Anastasia Chli, Ntina Statiri, Helen Giamarellou

INFECTIOUS DISEASES (2016)

Article Infectious Diseases

Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration

Ilias Karaiskos, Lena E. Friberg, Lambrini Galani, Konstantinos Ioannidis, Emmanouela Katsouda, Zoe Athanassa, Harris Paskalis, Helen Giamarellou

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)

Article Infectious Diseases

Epidemiology of infections caused by polymyxin-resistant pathogens

Helen Giamarellou

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)

Article Infectious Diseases

Impact of patients' professional and educational status on perception of an antibiotic policy campaign: a pilot study at a university hospital

Efthymia Giannitsioti, Sofia Athanasia, Diamantis Plachouras, Stavroula Kanellaki, Fani Bobota, Georgia Tzepetzi, Helen Giamarellou

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2016)

Review Infectious Diseases

Combination therapy for extensively-drug resistant gram-negative bacteria

Ilias Karaiskos, Anastasia Antoniadou, Helen Giamarellou

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2017)

Review Biochemistry & Molecular Biology

Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens

Ilias Karaiskos, Irene Galani, Maria Souli, Helen Giamarellou

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)

Article Infectious Diseases

Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producingKlebsiella pneumoniaeof sequence type 39 during treatment

Irene Galani, Ilias Karaiskos, Evdokia Angelidis, Vassiliki Papoutsaki, Lamprini Galani, Maria Souli, Anastasia Antoniadou, Helen Giamarellou

Summary: Three ceftazidime-avibactam-resistant KPC-2-producing Klebsiella pneumoniae strains of ST39 were isolated in Greece, with two strains corresponding to KPC-33 and KPC-57, and the third strain corresponding to KPC-44.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)

Review Infectious Diseases

Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel β-lactam-β-lactamase inhibitor combinations

Irene Galani, Ilias Karaiskos, Helen Giamarellou

Summary: Multi-drug-resistant Klebsiella pneumoniae is a major concern in bacterial resistance, with reports of strains developing resistance to Ceftazidime-Avibactam during treatment. Understanding the mechanisms of resistance can help improve the efficacy of current antimicrobials and guide the design of novel therapeutic agents that can overcome resistance mechanisms.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)

Review Infectious Diseases

Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies

Ilias Karaiskos, Irene Galani, Vassiliki Papoutsaki, Lamprini Galani, Helen Giamarellou

Summary: The emergence of carbapenemase resistant Gram-negative bacteria is a major public health concern. The review highlights new treatments for infections caused by carbapenemase producing Klebsiella pneumoniae, with a focus on novel antibiotics and beta-lactamase inhibitors. Approvals and developments of new antimicrobial agents show promising outcomes in combating CPKP infections, with potential for improved efficacy and safety profiles in future therapeutic strategies against multidrug-resistant K. pneumoniae.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)

No Data Available